Pelago Bioscience AB signs a strategic agreement with Cancer Research Horizons to unlock quantitative assessment of cellular target engagement across its pipeline of novel oncology programmes. The company will provide their well-established solutions to support Cancer Research Horizons in their quest of finding new cancer treatments.

“Cancer Research Horizons is an innovation leader in cancer research and oncology drug discovery and have unparalleled access to the finest scientific minds in the field. We are very happy to be able to provide Cancer Research Horizons with our 10+ years of expertise and knowledge with supporting pharmaceutical companies to help ensure their projects are on-target and to be able to help Cancer Research Horizons in their effort to beat cancer”

– Michael Dabrowski, CEO, Pelago Bioscience


“Cancer Research Horizons passionately recognise the importance of building and investing in tools and technologies regarded as critical for enabling deeper mechanistic understanding of our targets and their interactions with ligands. Quantitative assessment of cellular target engagement through Pelago Bioscience’s Cellular Thermal Shift Assay (CETSA®) is one such technology: this will form a key part of our drug discovery toolbox, helping to build a robust data package for our therapeutic discovery programmes and, ultimately, improve translation to patient benefit.”

– Dr Rachel Grimley, SVP Drug Discovery, Cancer Research Horizons

About Cancer Research Horizons

Cancer Research Horizons is the innovation engine of Cancer Research UK – the world’s largest charitable funder of cancer research. We bring together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.

To date, we’ve played an instrumental role in forming over 70 spin-out companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients across the world.

With access to Cancer Research UK’s network of 4,000 exceptional researchers, and £400+ million of annual research spend, we’re a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, spinout creation, and offer a full spectrum of drug discovery and clinical capabilities.

Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered.

For more information and to get in touch with the team, visit

About Pelago Bioscience

Pelago Bioscience was founded in 2013 and is today a fast-growing drug discovery focused contract research organization (CRO) with a service offering centered around its patented Cellular Thermal Shift Assay (CETSA®) technology. CETSA provides unique value to customers in accelerating drug discovery projects. Our approach is designed to help you make better decisions faster, no matter where you are in the drug discovery process.